Aeterna Zentaris Inc (AEZS)

6.340
-0.040(-0.63%)
  • Volume:
    308
  • Bid/Ask:
    6.250/6.400
  • Day's Range:
    6.240 - 6.340

AEZS Overview

Prev. Close
6.38
Day's Range
6.24-6.34
Revenue
3.3M
Open
6.26
52 wk Range
5.375-31
EPS
-2.41
Volume
308
Market Cap
30.79M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,058
P/E Ratio
-2.05
Beta
1.71
1-Year Change
-71.96%
Shares Outstanding
4,855,880
Next Earnings Date
Nov 10, 2022
What is your sentiment on Aeterna Zentaris?
or
Market is currently closed. Voting is open during market hours.

Aeterna Zentaris Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Aeterna Zentaris Inc Analysis

Aeterna Zentaris Inc Company Profile

Aeterna Zentaris Inc Company Profile

Employees
12
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA0079755017
  • CUSIP:007975501

Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyNeutralStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralSellStrong Sell
  • will this go back up?
    1
    • why?!
      0
      • Bloomberg business announced today "WHO has recommended the Oxford AEterna Zentaris vaccine for adults over 18"
        0
        • should we hold or short
          1
        • why short?
          0
      • Buy the dippp
        0
        • is it still a good buy?
          0
          • Probably back up to eighth within a week
            0
            • sounds good
              0
          • anyone knows how up it will go
            0
            • yes we have a crystal ball
              0
          • Here we go zhold tight
            0
            • Good things are coming soon
              0